You are viewing: Europe Latent TB Testing Market analysis
Part of: Latent TB Testing Market (Global)

The Europe Latent TB Testing Market was valued at $134.2 Million in 2024 and projected to reach to $183.6 Million by 2029, representing a compound annual growth rate of 6.5%. Europe's latent TB testing market is positioned for steady growth through 2029, driven by comprehensive TB elimination strategies and enhanced screening protocols across EU member states.

Europe Latent TB Testing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Latent TB Testing Market Trends and Insights

  • This growth trajectory reflects Europe's commitment to tuberculosis elimination strategies and increased screening initiatives across member states.
  • Europe's healthcare infrastructure and regulatory frameworks support widespread adoption of advanced diagnostic technologies for latent TB detection. The European market benefits from strong public health policies, rising awareness of TB transmission risks, and integration of latent TB testing into routine clinical practice.
  • Europe's aging population and immigration patterns contribute to sustained demand for comprehensive TB screening programs.
  • Between 2024 and 2029, Europe is expected to see accelerated investment in point-of-care testing solutions and digital health integration within TB control programs..

Key Market Statistics

  • CAGR (2024-2029) 6.5% CAGR
  • Market Size, 2024 ~USD 134.2 Million
  • Forecast, 2029 ~USD 183.6 Million
  • Geography Europe

Europe Latent TB Testing Market Overview

Market Valuation & Growth :

Europe's latent TB testing market is valued at $134.2 million in 2024, with a robust 6.5% CAGR projected through 2029, reaching $183.6 million. This outpaces the global growth rate of 5.8%, demonstrating Europe's accelerated commitment to TB elimination.

Strong Healthcare Infrastructure :

Europe's advanced healthcare systems and stringent regulatory frameworks enable rapid adoption of innovative latent TB diagnostic technologies. EU member states' coordinated TB elimination strategies drive consistent market expansion across the region.

Key Market Leaders :

Germany ($31.96M), UK ($38.34M), and France ($28.29M) represent the largest European markets, collectively accounting for over 60% of regional demand. These nations lead in screening initiatives and healthcare investment.

Screening & Prevention Focus :

Increased TB screening initiatives across European member states, coupled with immigration-related testing requirements and occupational health programs, are driving sustained demand for latent TB diagnostic solutions.

Europe Latent TB Testing Market Dynamics

  • The region's mature healthcare infrastructure and regulatory support create favorable conditions for advanced diagnostic adoption.
  • Increasing awareness of latent TB infection risks, particularly among high-risk populations including migrants and healthcare workers, continues to expand the testing base.
  • Investment in point-of-care testing technologies and integration with digital health systems further accelerates market penetration across European nations..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • CONMED Corporation

    Key Takeaways

    • Europe's latent TB testing market will grow from $134.2M (2024) to $183.6M (2029) at a 6.5% CAGR
    • Europe's robust healthcare infrastructure and TB elimination policies drive consistent market expansion
    • Europe's aging population and migration patterns sustain demand for comprehensive TB screening
    • Europe is investing in point-of-care and digital health solutions for latent TB detection by 2029

    Latent TB Testing Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment HOUSEHOLD CONTACTS WITH PULMONARY TB (Application)
    Forecast Period 2024-2029
    Growth Rate CAGR of 5.8% from 2024 to 2029
    Largest Segment IGRA (Test Type)
    Market Size Base Year (Billions) ~USD 0.58 (2024)
    Revenue Forecast (Billions) ~USD 0.77 (2029)
    Segments Covered Test Type, Application, End User

    Europe Latent TB Testing Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Test Type

    • Igra
    • Tst

    By Application

    • Household Contacts With Pulmonary Tb
    • Other Applications
    • People Living With Hiv

    By End User

    • Academic & Research Institutes
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Other End Users

    REST OF EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES0.60.710.740.790.850.910.991.087.8
    DIAGNOSTIC LABORATORIES7.559.149.8210.6311.6312.8114.2115.8310
    HOSPITALS & CLINICS2.312.752.913.13.343.623.964.348.4
    OTHER END USERS0.510.60.620.660.70.750.820.897.3
    TOTAL10.9613.214.115.1816.5218.119.9722.149.4

    EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES7.899.119.329.6210.0310.5311.1311.824.9
    DIAGNOSTIC LABORATORIES74.7788.1192.0997.02103.24110.64119.39129.437
    HOSPITALS & CLINICS23.1426.8327.628.6229.9731.6233.5935.865.4
    OTHER END USERS4.425.085.195.345.555.86.116.474.5
    TOTAL110.22129.13134.19140.59148.79158.59170.23183.586.5

    Target Audience

    • Diagnostic Device Manufacturers : Evaluate market potential for latent TB testing solutions across European markets. Understand regional demand patterns, competitive positioning, and regulatory pathways for product launches and market expansion.
    • Healthcare System Administrators : Optimize TB screening programs and resource allocation across European healthcare networks. Access market data to justify investments in latent TB testing infrastructure and justify budget allocations.
    • Pharmaceutical & Biotech Companies : Identify opportunities for TB treatment and prevention product development in Europe. Understand patient populations, screening volumes, and market readiness for innovative latent TB management solutions.
    • Investment & Private Equity Firms : Assess investment opportunities in European TB diagnostics and healthcare companies. Evaluate market growth potential, competitive dynamics, and exit opportunities in this expanding healthcare segment.
    • Public Health & Government Agencies : Support TB elimination strategy development with evidence-based market data. Benchmark screening programs, identify funding gaps, and align public health initiatives with market trends across European nations.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 239.8 Million · 2.8% wtd CAGR ·
    Asia Pacific
    ~USD 298.7 Million · 8.1% wtd CAGR ·
    Latin America
    ~USD 44.9 Million · 7.4% wtd CAGR ·
    Middle East & Africa
    ~USD 6.4 Million · 5.7% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    UKUSD 38.34 Million
    FranceUSD 28.29 Million
    GermanyUSD 31.96 Million
    SpainUSD 19.26 Million
    ItalyUSD 16.72 Million
    BelgiumUSD 4.47 Million
    RussiaUSD 3.8 Million
    SwedenUSD 2.25 Million
    DenmarkUSD 1.27 Million
    Rest Of EuropeUSD 20.71 Million

    Country market size visualization

    UK
    USD 38.34 Million
    France
    USD 28.29 Million
    Germany
    USD 31.96 Million
    Spain
    USD 19.26 Million
    Italy
    USD 16.72 Million
    Belgium
    USD 4.47 Million
    Russia
    USD 3.8 Million
    Sweden
    USD 2.25 Million
    Denmark
    USD 1.27 Million
    Rest Of Europe
    USD 20.71 Million

    Reasons to Buy this Report

    • Regional Market Segmentation : Detailed breakdown of Europe's latent TB testing market by country, including Germany, UK, France, Spain, and Italy, enabling targeted market entry and expansion strategies specific to each European nation.
    • Growth Trajectory Analysis : Comprehensive insights into Europe's 6.5% CAGR through 2029, outpacing global growth rates. Understand market drivers, regulatory tailwinds, and investment opportunities unique to the European region.
    • Competitive Landscape Intelligence : Identify leading diagnostic providers, emerging technologies, and market consolidation trends across European markets. Benchmark your positioning against regional competitors and understand market share dynamics.
    • Regulatory & Policy Framework : Navigate Europe's complex healthcare regulations, EU directives, and national TB elimination programs. Gain insights into reimbursement policies, certification requirements, and market access strategies by country.
    • Strategic Investment Guidance : Data-driven recommendations for market entry, partnership opportunities, and resource allocation across high-growth European markets. Identify underserved regions and emerging opportunities for expansion.

    Frequently asked questions

    What is the current size of Europe's latent TB testing market?

    Europe's latent TB testing market was valued at $134.2 million in 2024 and is expected to reach $183.6 million by 2029.

    What is the projected growth rate for latent TB testing in Europe?

    Europe's latent TB testing market is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2029.

    What factors are driving growth in Europe's latent TB testing market?

    Growth in Europe is driven by strong public health policies, TB elimination initiatives, aging populations, migration patterns, and increased adoption of advanced diagnostic technologies.

    Which testing technologies are gaining traction in Europe's latent TB market?

    Europe is seeing increased adoption of point-of-care testing solutions, interferon-gamma release assays (IGRAs), and digital health-integrated TB screening platforms.

    How does Europe's healthcare infrastructure support latent TB testing expansion?

    Europe's robust regulatory frameworks, integrated public health systems, and investment in diagnostic infrastructure enable widespread latent TB testing implementation across member states.

    RESEARCH METHODOLOGY

    The study involved major activities in estimating the current market size for the latent TB testing market. Exhaustive secondary research was done to collect information on the latent TB testing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the latent TB testing market.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME DESIGNATION
    QIAGEN General Manager
    Revvity Area Sales Manager

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the latent TB testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the latent TB testing market have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    The research methodology used to estimate the market size includes the following:

    Data Triangulation

    After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Latent tuberculosis testing refers to diagnosing the infection by detecting an immune response to Mycobacterium tuberculosis antigens using either the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). These tests help identify dormant tuberculosis infections in individuals without active symptoms.

    Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department  
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global latent TB testing market, by test type, application, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall latent TB testing market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

     

    Get the Full Latent TB Testing Market Report

    Full forecast, segment splits, and company analysis for all Latent TB Testing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status